BioReact
Category: AI in Healthcare
An AI-powered bioprocess optimization platform that automates data alignment and parameter modeling to accelerate biological manufacturing and drug development. BioReact was founded in 2023. The company is led by Mitchell J. Castetter. Based in Indianapolis, USA. Team size: 1-10. Total funding raised: $1.22M. Latest round: Strategic Investment (Feb 2025). Key investors include New Stack Ventures, Techstars, Hurricane Ventures, PhyCap Fund, Service Provider Capital.
- Founded
- 2023
- Headquarters
- Indianapolis, USA
- Team size
- 1-10
- Total funding
- $1.22M
Value proposition
Reduces manual data cleaning and physical experiment cycles by automatically aligning disparate bioreactor datasets and simulating thousands of in-silico experiments to identify optimal growth conditions.
Products and solutions
AI-Powered Bioprocess Platform (Core), Automated Time-Series Data Alignment Engine, In-silico Experiment Simulator (up to 10,000 virtual runs), Predictive Parameter Optimization Suite (pH, temperature, and media composition)
Unique value
Equipment-agnostic architecture that automatically synchronizes online bioreactor data with offline analytical results, solving the 'data silo' bottleneck in bioprocessing.
Target customer
Bioprocess scientists, R&D engineers, and lab managers in biopharma, synthetic biology, and industrial biotechnology.
Industries served
Biotechnology, Pharmaceuticals, Synthetic Biology, Cultured Meat, Industrial Fermentation
Technology advantage
Combines proprietary machine learning algorithms with high-scale simulation capabilities to minimize physical lab runs, led by a founding team with deep expertise in biotech sales (Cytena/Beckman Coulter) and bioinformatics.
How they differentiate
BioReact differentiates through an equipment-agnostic AI architecture that specifically solves the 'data silo' problem by automatically aligning real-time (online) bioreactor data with manual (offline) analytical lab results, reducing the need for physical experiments via high-scale in-silico simulations.
Main competitors
DataHow, Culture Biosciences, TeselaGen
Key partnerships
Techstars (2024 Cohort), Hurricane Ventures (University of Tulsa), Synonym Bio (Strategic Pilot Partner), gBETA Accelerator, New Stack Ventures
Notable customers
Synonym Bio (Strategic Pilot Partner)
Major milestones
Accepted into gBETA accelerator program in 2023, Selected for Techstars Chicago 2024 cohort, Winner of the Indiana Innovation Association (IIA) Pitch Summit, Secured strategic investment from University of Tulsa’s Hurricane Ventures in February 2025
Growth metrics
Alumnus of Techstars 2024; Winner of the IIA Pitch Summit in Silicon Valley.
Market positioning
Early-stage specialized AI-SaaS provider for bioprocess R&D and optimization.
Geographic focus
North America (primarily United States)
Patents and IP
Proprietary AI algorithms and trade secrets; specific public patent filings not disclosed as of latest update.
About Mitchell J. Castetter
Mitchell Castetter has over a decade of experience in biotechnology sales and leadership. Prior to founding BioReact, he served as a Key Account Manager at Cytena and spent several years at Beckman Coulter Life Sciences in various sales and account management roles. He began his entrepreneurial journey during his undergraduate studies at Ball State University, where he developed e-commerce and dropshipping technologies.
Official website: https://www.bioreact.co